Pancreatic Cancer Research

ResearcherShanghai UniversityActive in the last 2 years

Yangsen Cao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5101003599. Sources: OpenAlex.

Their work

Papers
26 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 1 paper · 2020: 2 papers · 2021: 6 papers · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 26

  1. ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1080/14796694.2025.2522061↗
  2. Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. Co-author DOI 10.1080/1750743x.2025.2533112↗
  3. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. Co-author DOI 10.1016/j.radonc.2023.109941↗
  4. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s13014-024-02493-8↗
  5. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabi… Co-author DOI 10.1016/j.eclinm.2022.101764↗
  6. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… First author DOI 10.1016/s1470-2045(22)00066-3↗
  7. Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer:… Co-author DOI 10.1136/bmjopen-2021-049382↗
  8. Uniform expansion vs. non-uniform expansion of gross tumor volume based on recurrence patterns to form planning target volume of stereotactic body radiation th… Co-author DOI 10.21203/rs.3.rs-1919548/v1↗
  9. Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic ca… Co-author DOI 10.3389/fonc.2022.1021058↗
  10. Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single… First author DOI 10.1016/j.radonc.2021.07.009↗
  11. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… First author DOI 10.1016/s1470-2045(21)00286-2↗
  12. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply. First author DOI 10.1016/s1470-2045(21)00529-5↗
  13. Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. First author DOI 10.1111/cas.14486↗
  14. Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. Co-author DOI 10.3389/fonc.2021.688576↗
  15. Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Cons… Co-author DOI 10.3389/fonc.2021.729490↗
  16. Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. First author DOI 10.1177/1758835920977155↗
  17. Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of m… Co-author DOI 10.20892/j.issn.2095-3941.2019.0101↗
  18. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Tar… Co-author DOI 10.1016/j.ijrobp.2019.01.075↗
  19. Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1002/cam4.1553↗
  20. Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD scor… Co-author DOI 10.1016/j.radonc.2018.08.012↗
  21. Optimization of dose distributions of target volumes and organs at risk during stereotactic body radiation therapy for pancreatic cancer with dose-limiting aut… Co-author DOI 10.1186/s13014-018-0956-7↗
  22. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matc… Co-author DOI 10.2147/cmar.s163655↗
  23. Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pa… Co-author DOI 10.2147/cmar.s166713↗
  24. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Co-author DOI 10.1002/cam4.1164↗
  25. Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I st… Co-author DOI 10.1186/s13014-016-0760-1↗
  26. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally adva… Co-author DOI 10.1136/bmjopen-2016-013220↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huojun Zhang · 25 shared papers, 2016–2025 · strength 3.36
  2. Xiaofei Zhu · 24 shared papers, 2016–2025 · strength 3.29
  3. Lingong Jiang · 14 shared papers, 2020–2025 · strength 2.48
  4. Yusheng Ye · 12 shared papers, 2020–2025 · strength 2.06
  5. Wenyu Liu · 9 shared papers, 2018–2025 · strength 1.66
  6. Shuiwang Qing · 13 shared papers, 2016–2021 · strength 1.21
  7. Yuxin Shen · 10 shared papers, 2016–2021 · strength 0.88
  8. Gang Jin · 2 shared papers, 2021–2022 · strength 0.29
  9. Xiaofei Zhu · 1 shared paper, 2025 · strength 0.25
  10. Ting‐Shi Su · 2 shared papers, 2020–2021 · strength 0.23
  11. Xixu Zhu · 1 shared paper, 2021 · strength 0.12
  12. Di Chen · 1 shared paper, 2020 · strength 0.11
  13. Zhitao Dai · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.